TMAO: a potential mediator of clopidogrel resistance

[1]  A. Duttaroy.  Role of Gut Microbiota and Their Metabolites on Atherosclerosis, Hypertension and Human Blood Platelet Function: A Review , 2020, Nutrients.

[2]  Shuo Liu,et al.  Association between red cell distribution width level and risk of stroke , 2020, Medicine.

[3]  S. Hazen,et al.  Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. D. Di Minno,et al.  Association of human leukocyte antigen-G 14 bp polymorphism with recurrent pregnancy loss in European countries: a meta-analysis of literature studies. , 2019, Fertility and sterility.

[5]  H. Arnesen,et al.  A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease , 2019, Thrombosis Journal.

[6]  A. Sannino,et al.  Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases. , 2019, Trends in cardiovascular medicine.

[7]  Yuesong Pan,et al.  High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies , 2019, Scandinavian cardiovascular journal : SCJ.

[8]  H. Büller,et al.  Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease? , 2018, Journal of thrombosis and haemostasis : JTH.

[9]  M. Fischbach,et al.  Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential , 2018, Circulation research.

[10]  Jennifer M. Brown,et al.  Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N‐oxide‐generating pathway, modulates platelet responsiveness and thrombosis risk , 2018, Journal of thrombosis and haemostasis : JTH.

[11]  S. Hazen,et al.  Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential , 2018, Nature Medicine.

[12]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[13]  A. Sannino,et al.  Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis , 2017, European heart journal.

[14]  S. Zeisel,et al.  Trimethylamine N-Oxide, the Microbiome, and Heart and Kidney Disease. , 2017, Annual review of nutrition.

[15]  Yue Han,et al.  Circulating trimethylamine N‐oxide and the risk of cardiovascular diseases: a systematic review and meta‐analysis of 11 prospective cohort studies , 2017, Journal of cellular and molecular medicine.

[16]  J. Manson,et al.  Gut Microbiota Metabolites and Risk of Major Adverse Cardiovascular Disease Events and Death: A Systematic Review and Meta‐Analysis of Prospective Studies , 2017, Journal of the American Heart Association.

[17]  Joo-In Park,et al.  Platelet Activation: The Mechanisms and Potential Biomarkers , 2016, BioMed research international.

[18]  S. Hazen,et al.  Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk , 2016, Cell.

[19]  P. Dobesh,et al.  Clopidogrel Response Variability , 2016, Journal of pharmacy practice.

[20]  Zhang Changjiang,et al.  The Protective Role of Interleukin-33 in Myocardial Ischemia and Reperfusion Is Associated with Decreased HMGB1 Expression and Up-Regulation of the P38 MAPK Signaling Pathway , 2015, PloS one.

[21]  D. Trenk,et al.  Genetics of platelet inhibitor treatment. , 2014, British journal of clinical pharmacology.

[22]  S. Hazen,et al.  Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. , 2013, The New England journal of medicine.

[23]  W. Cohen,et al.  Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. , 2013, The American journal of cardiology.

[24]  A. Gori,et al.  Reticulated platelets predict cardiovascular death in acute coronary syndrome patients , 2013, Thrombosis and Haemostasis.

[25]  M. Fromm,et al.  Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement. , 2010, Journal of the American College of Cardiology.

[26]  Deepak L. Bhatt,et al.  Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[27]  J. O’Connell,et al.  Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. , 2009, JAMA.

[28]  R. Koppensteiner,et al.  Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition , 2009, Heart.

[29]  S. Steinhubl,et al.  Platelet function monitoring in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.

[30]  N. Lakkis,et al.  Reticulated platelets in acute coronary syndrome: a marker of platelet activity. , 2004, Journal of the American College of Cardiology.

[31]  Y. Sugiyama,et al.  Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[32]  H. Yamazaki,et al.  Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions , 2000, European Journal of Clinical Pharmacology.

[33]  M. Valdés,et al.  Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes , 2018, Journal of cardiovascular pharmacology and therapeutics.

[34]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[35]  David Brink,et al.  : A Review of the , 2018 .

[36]  R. Krauss,et al.  Supplemental materials for: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis , 2013 .